Inventiva restarts PhIII screening for MASH trial; CDMO announces small public offering

Plus, news about Zymeworks:

In­ven­ti­va re­sumes screen­ing in PhI­II MASH tri­al: The biotech lift­ed a vol­un­tary pause it had placed on a reg­is­tra­tional study of lan­i­fi­bra­nor in Feb­ru­ary af­ter an un­ex­pect­ed ad­verse event. The com­pa­ny has im­ple­ment­ed the rec­om­men­da­tions of an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee, in­clud­ing mon­i­tor­ing pa­tients’ liv­ers every six weeks. US-list­ed shares $IVA were up about 5% on Fri­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.